Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) Operating Expenses: 2017-2024

Historic Operating Expenses for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to $39.9 million.

  • Solid Biosciences' Operating Expenses rose 79.19% to $39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $129.7 million, marking a year-over-year increase of 24.44%. This contributed to the annual value of $129.7 million for FY2024, which is 24.44% up from last year.
  • Latest data reveals that Solid Biosciences reported Operating Expenses of $39.9 million as of Q4 2024, which was up 13.40% from $35.2 million recorded in Q3 2024.
  • Solid Biosciences' 5-year Operating Expenses high stood at $39.9 million for Q4 2024, and its period low was $19.0 million during Q2 2020.
  • Over the past 3 years, Solid Biosciences' median Operating Expenses value was $27.3 million (recorded in 2022), while the average stood at $28.8 million.
  • As far as peak fluctuations go, Solid Biosciences' Operating Expenses crashed by 35.59% in 2023, and later spiked by 79.19% in 2024.
  • Solid Biosciences' Operating Expenses (Quarterly) stood at $21.3 million in 2020, then reached $34.6 million in 2022, then crashed by 35.59% to $22.3 million in 2023, then skyrocketed by 79.19% to $39.9 million in 2024.
  • Its Operating Expenses stands at $39.9 million for Q4 2024, versus $35.2 million for Q3 2024 and $27.8 million for Q2 2024.